This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The ...

Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...

For 2025, Pfizer forecast revenue between $61 billion and $64 billion, as well as adjusted earnings per share in the range of ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Pfizer Inc. (NYSE: PFE) reported a strong performance for the fourth quarter of 2024, with revenues reaching $17.8 billion.

(Reuters) -U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strong sales of ...

EST Pfizer (PFE) says on track to deliver ~$4.5B in cost savings by end of 2025Maximize Your Portfolio with Data Driven Insights:Leverage ...

Citi reaffirmed its Buy rating and $13.00 price target for ORIC Pharmaceuticals (NASDAQ:ORIC), whose stock currently trades at $10.15. The company has shown strong momentum with a 25.77% year-to-date ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Pfizer expects full-year earnings in the range of $2.80 to $3 per share, with revenue in the range of $61 billion to $64 billion. This story was generated by Automated Insights ( ...

U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...